Ticlopidine Hcl Articles
Japan stock market week to April 16, 2007
23 April 2007
Taiwan acts to curb pharma "overuse"
15 August 2005
Caraco expects $35M revenues in 2003
24 February 2003
Net income leaps 50% at Roche in 2000, but pharma sales disappoint
28 February 2001
Sanofi-Synthelabo sales push $1.3 billion
26 April 2000
Sanofi-Synthelabo sales up 9% in 3rd quarter
1 November 1999
Sanofi-Synthelabo 1st-half profits up 18%
1 September 1999
First ticlopidine generic approved in USA
8 July 1999
Japan MHW mandates Panaldin label change
6 July 1999
New drugs boost Sanofi's 1998 sales
27 January 1999
New drugs boost Sanofi's 1998 sales
25 January 1999
Sanofi-Synthelabo Merger Strong In Cardio, CNS
10 December 1998
Sanofi-Synthelabo Planning To Go Shopping In USA
4 December 1998
US Seniors "Pay Up To 1,407% More For Rx Drugs"
29 September 1998
Sanofi And BMS Launch Plavix In Europe
8 September 1998
Sanofi First-Half Profits Climb 12%
2 September 1998
Purepac et al Challenge FDA On Generics Rules
24 July 1998
Sanofi Produces Strong First-Half Sales Growth
24 July 1998
17% Pharma Growth Boosts Sanofi 1st-Qtr Sales
24 April 1998
Warnings For Sanofi's Ticlid
8 April 1998
Combining Drugs With Interventional Cardiology
8 April 1998
Roche Sales Soar In 1st Quarter 1998
7 April 1998
Sanofi/B-MS Launch Plavix In First Market, USA
1 April 1998
R-PR's Lovenox Cleared In USA For Angina
31 March 1998
Sanofi Pharma Sales Held Back In West Europe, But Up 10%
4 February 1998
Sanofi/B-MS' Clopidogrel Backed By US Panel
30 October 1997
Sanofi's First Half 1997 Net Earnings Rise 10%
4 September 1997
First-Quarter Sales At Roche Up 18%
21 April 1997
Positive Verdict On Roche's Posicor From FDA Panel
10 March 1997
Strong Sales At Sanofi In 4th Qtr
17 February 1997
EUROPEAN AND LONDON STOCK COMMENTS
18 November 1996
Clopidogrel Tops Aspirin For Atherosclerotic Disease
18 November 1996
Sanofi Set For Expansion In Sth Africa With OmniMed
18 November 1996
US FDA Seeks Comments On Consumer Ad Labeling
27 May 1996
"Favorable Growth " At Sanofi In 1995
25 March 1996
Sanofi's Mid-term Pipeline "One Of The Most Promising
23 October 1995
Sankyo To Develop Searle's Xemilofiban In Japan
7 August 1995
Syntex Patient Compliance Program
18 July 1994
ITALIAN POLICE SEIZE ILLICIT DRUGS MONEY
27 June 1994
SYNTEX CHIEF SPEAKS ON PRODUCT PROSPECTS
24 January 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
SYNTEX EXPECTS PATENT EXPIRY EFFECTS
13 December 1993
"GOOD GROWTH" SAYS ELF SANOFI IN 3rd QTR
8 November 1993
DAIICHI ENTERING NEW PRODUCT PHASE
26 July 1993
SYNTEX PROFITS HIT BY RESTRUCTURING
7 June 1993
GERMANY APPROVES TICLID EXTENSION
29 March 1993
SPENDING CONTROL AT SYNTEX IN Q2
8 March 1993
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
ELF SANOFI SALES
7 September 1992
SYNTEX INVESTMENT FOR FUTURE GROWTH
29 June 1992
SANOFI SEEKS JAPANESE ALLIANCES
11 May 1992
SANOFI SEEKS JAPANESE ALLIANCES
11 May 1992
SANOFI STREAMLINES, SELLING BEAUTY LINES
20 January 1992
SANOFI, CIBA-GEIGY ON PARIBAS BUY LIST
13 January 1992
US FDA BEATS 1990 DRUG APPROVALS IN 1991
13 January 1992
SANOFI'S TICLID LAUNCHED IN AUSTRALIA
6 January 1992
Showing 1-63 of 63 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
